Clinical Trial Update: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NANT immunotherapy for resectable non-small cell lung cancer has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NANT immunotherapy

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN